MétaCan
Menu
Back to cohort

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

2021· article· en· W3200845029 on OpenAlexaff
David A. Bond, Jeffrey M. Switchenko, Diego Villa, Kami J. Maddocks, Michael C. Churnetski, Alina S. Gerrie, Subir Goyal, Krithika Shanmugasundaram, Oscar Calzada, Bhaskar Kolla, Veronika Bachanová, James N. Gerson, Stefan K. Barta, Brian T. Hill, Yazeed Sawalha, Peter Martin, Edward Maldonado, Max J. Gordon, Alexey V. Danilov, Natalie S. Grover, Stephanie Mathews, Madelyn Burkart, Reem Karmali, Nilanjan Ghosh, Steven Park, Narendranath Epperla, Talha Badar, Jin Guo, Mehdi Hamadani, Timothy S. Fenske, Mary‐Kate Malecek, Brad S. Kahl, Christopher R. Flowers, Kristie A. Blum, Jonathon B. Cohen

Bibliographic record

VenueBlood Advances · 2021
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsSpinal Cord Injury BCUniversity of British Columbia
FundersNational Center for Advancing Translational SciencesPharmacyclicsSanofi GenzymeTakeda OncologyGenentechWinship Cancer InstituteSeagenIncyteAstellas PharmaAdaptive BiotechnologiesTG TherapeuticsH. Lundbeck A/SBeiGenePurdue PharmaRegeneron PharmaceuticalsNational Institutes of HealthOhio State UniversityOmeros CorporationVerastem OncologySpectrum PharmaceuticalsAtara BiotherapeuticsNational Cancer InstituteGilead SciencesSanofiPurdue UniversityMorphoSysCelgeneBristol-Myers SquibbAstraZenecaEmory University
KeywordsMedicineIntensive careOncologyInternal medicineIntensive care medicine

Abstract

fetched live from OpenAlex

Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) after first-line therapy among 455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive disease during induction or POD within 6 months of diagnosis (n = 65; 14%); POD6-24, defined as POD between 6 and 24 months after diagnosis (n = 153; 34%); and POD>24, defined as POD >24 months after diagnosis (n = 237; 53%). The median overall survival from POD (OS2) was 1.3 years (95% confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95% CI, 6.2-NR) for those with POD>24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until POD was replicated in an independent cohort of 245 patients with relapsed MCL, with median OS2 of 0.3 years (95% CI, 0.1-0.5) for PRF/POD6, 0.8 years (95% CI, 0.6-0.9) for POD6-24, and 2.4 years (95% CI 2.1-2.7) for POD>24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.259
Teacher spread0.244 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations41
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicLymphoma Diagnosis and TreatmentFrench-language works237,207